HLS Therapeutics ( TSE:HLS ) Third Quarter 2024 Results Key Financial Results Revenue: US$14.1m (down 12% from 3Q...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and nine months ended September 30, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.